Patient characteristics and immunosuppressive drug regimens in transplant recipients depending on graft type and time after transplantation
| Renal longitudinal | p-value | Renal cross-sectional | Lung cross-sectional | p-value | ||
| Subjects (males/females) n | 13 (8/5) | 49 (26/23) | 49 (26/23) | |||
| Time after transplantation | 3 months | 12 months | >12 months (5.7±3.7 yrs) | >12 months (4.2±2.5 yrs) | ||
| Age yrs | 55.1±8.3 | 48.4±14.1 | 48.4±14.3 | |||
| Triple/double drug regimen | 13/0 | 2/11 | <0.0001 | 5/44 | 49/0 | <0.0001 |
| Calcineurin inhibitor | ||||||
| Cyclosporine A ng·mL−1 | 167.9±20.7 | 104.1±6.7 | 0.004 | 109.1±26.0 | 176.4±90.5 | <0.0001 |
| Subjects n | 4 | 4 | 28 | 35 | ||
| Tacrolimus ng·mL−1 | 11.4±2.6 | 7.6±2.6 | 0.04 | 7.8±1.9 | 8.9±3.6 | ns |
| Subjects n | 9 | 9 | 21 | 14 | ||
| Azathioprine mg·day−1 | 50–150 | 50–150 | 50–150 | 50–150 | ||
| Methylprednisolone#/prednisolone¶ mg·day−1 | 8–20 | ≤4 | ≤4 | 7.5 | ||
| Mycophenolate mofetil g·day−1 | NA | ≤2 | ≤2 | ≤2 | ||
Data are presented as mean±sd (actual doses for cyclosporine A and tacrolimus, intended doses for other drugs) unless otherwise stated. NA: not applicable; NS: nonsignificant. #: renal transplant recipients; ¶: lung transplant recipients.